Supplementary

Dear editors and/or reviewers,

We previously conducted a three-dose experiment of HJZY capsule treating OAS with administration concentrations of 1.24 g/(kg·d), 0.62 g/(kg·d), 0.31 g/(kg·d) as high, medium, and low dosage. Here we provide results of the previous experiment in the figure below (*Figure S1*), and it's obvious that a dosage of 0.31 g/(kg·d) exerted the best overall effect on OAS. Thus, in the present study, we slightly increase the dosage to 0.35 g/(kg·d) as the administration concentration. Moreover, a time-dependent design was carried out in the present study to evaluate the self-curing effect of the CP-induced OAS model, so that the real curative effect of the HJZY capsule could be demonstrated. Concerning the 3R rules of animal experiments, we consequently decided on the single-dose, multi-timepoint design with intervention dose as 0.35 g/(kg·d) based on our previous results.

Once again, we sincerely appreciate your helpful suggestions for our manuscript. Please do not hesitate to contact us if needed.

Best regards, All authors.




Figure S1 Bars in red frames are from the HJZY capsule 0.31g/(kg·d) group in our previous and unpublished experiment. NS, normal saline. CP, cyclophosphamide. *, represent P<0.05, compared with the NS group; *, represent P<0.05, compared with the CP group.